Updated from ASH and ACCP – DOAC Dosing for VTE: What You Need to Know
Dr. Chokri Ben Lamine shared on X:
Based on ASH 2024 and ACCP 2021 Guidelines
”VTE Treatment (Therapeutic Anticoagulation)”
-Apixaban:
▸ 10 mg BID × 7 days → 5 mg BID
▸ Optional: 2.5 mg BID after 6 months (extended use)Rivaroxaban:
▸ 15 mg BID × 21 days → 20 mg OD
▸ Optional: 10 mg OD after 6 monthsEdoxaban:
▸ Parenteral anticoagulation × 5–10 days → 60 mg OD
▸ Reduce to 30 mg if CrCl 15–50 or weight ≤60 kgDabigatran:
▸ Parenteral anticoagulation × 5–10 days → 150 mg BIDVTE Prophylaxis (Post-op, High Risk)
-Apixaban: 2.5 mg BID-Rivaroxaban: 10 mg OD
-Dabigatran: 110 mg Day 1 → 220 mg OD
-Edoxaban: Not typically used for primary prophylaxis
Key Precautions
-Age >75-CrCl <30 mL/min
-Low body weight
-Active cancer → Consider LMWH
Always assess bleeding & renal function risk.”
You can Find more Posts on Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants
